Predictive value of PI-RADS score V2 in the Gleason score upgrading of prostate cancer patients with biopsy Gleason 3+3 after radical prostatectomy
GONG Huijie1,2, NIU Shaoxi3, YAN Yongji2, CHEN Zhengguang4, ZHANG Xu3
1 Department of Urology, the First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100700, China; 2 Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine; 3 Department of Urology, Center of Chinese PLA General Hospital; 4 Department of Radiology, Dongzhimen Hospital, Beijing University of Chinese Medicine
Abstract：Objective: To investigate the predictive value of mp-MRI-based PI-RADS score V2 in the pathological Gleason score upgrading of prostate cancer patients with prostate needle biopsy (Gleason=3+3) after radical prostatectomy. Methods： We retrospective evaluated 89 patients with pathologically proved prostate cancer with Gleason score =3+3 from January 2017 to January 2020. The clinical and pathological data including patient age, body mass index (BMI), prostate specific antigen (PSA) and PSA density (PSAD), PI-RADS score V2, biopsy relevant data and postoperative Gleason score were collected. Univariable and multivariable logistic regression analyses were used to identify predictors of Gleason score upgrading. Results： The postoperative Gleason score was 3+3 in 46 patients (51.7%), and upgraded to ≥7 in 43 patients (48.3%). Of the 43 upgraded patients, 38 patients got PI-RADS score of 4 or 5 points, accounting for 88.4%. Multivariate logistic regression analysis showed that PI-RADS score (HR = 32.6, 95%CI = 6.2-170.8, P < 0.01) and PSAD (≥ 0.20) (HR = 9.6, 95%CI = 1.3-69.7, P = 0.025) were predictors of Gleason score upgrading after prostatectomy. Conclusion： For prostate cancer patients with preoperative Gleason score of 3+3=6, multi-parameter MRI based PI-RADS score V2 and PSAD were independent predictors of Gleason score upgrading after radical prostatectomy.
巩会杰, 牛少曦, 闫永吉, 陈正光, 张旭. 前列腺影像报告和数据系统评分V2对穿刺为Gleason 3+3前列腺癌患者根治术后病理升级的预测价值研究[J]. 微创泌尿外科杂志, 2021, 10(4): 277-282.
GONG Huijie, NIU Shaoxi, YAN Yongji, CHEN Zhengguang, ZHANG Xu. Predictive value of PI-RADS score V2 in the Gleason score upgrading of prostate cancer patients with biopsy Gleason 3+3 after radical prostatectomy. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(4): 277-282.
[1] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2019. CA Cancer J Clin, 2019,69(1):7-34. [2] FENG RM, ZONG YN, CAO SM, et al.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond), 2019,39(1):22. [3] EVANS SM, PATABENDI BV, KRONBORG C, et al.Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria. Prostate Int, 2016,4(4):145-151. [4] SUN Y, REYNOLDS HM, PARAMESWARAN B, et al.Multiparametric MRI and radiomics in prostate cancer: a review. Australas Phys Eng Sci Med, 2019,42(1):3-25. [5] KING CR.Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer, 2000,90(6):305-311. [6] BARRETT T, HAIDER M.The emerging role of MRI in prostate cancer active surveillance and ongoing challenges. AJR Am J Roentgenol, 2017,208(1):131-139. [7] KASEL-SEIBERT M, LEHMANN T, ASCHENBACH RA, et al.Assessment of PI-RADS v2 for the detection of prostate cancer. Eur J Radiol, 2016,85(4):726-731. [8] WEINREB JC, BARENTSZ JO, CHOYKE PL, et al.PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol, 2016,69(1):16-40. [9] YIM JH, KIM CK, KIM JH.Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2. J Magn Reson Imaging, 2018,47(4):1072-1079. [10] ZHAI L, FAN Y, SUN S, et al.PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3?+?3 prostate cancer. Scand J Urol, 2018,52(5/6):333-339. [11] ZHAI L, FAN Y, MENG Y, et al.The role of Prostate Imaging Reporting and Data System score in Gleason 3?+?3 active surveillance candidates enrollment: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis, 2019,22(2):235-243. [12] MAGHELI A, HINZ S, HEGE C, et al.Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series:a single center experience. J Urol, 2010,183(1):126-131. [13] OH JJ, HONG SK, LEE JK, et al.Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int, 2012,110(11 Pt B):E494-E499. [14] 黄遂斌,吕磊,向威等.低危型前列腺癌患者术前穿刺病理Gleason评分发生术后病理升级的相关因素分析.临床泌尿外科杂志,2018,33(9):726-729.
